PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors

Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgroup. The aim of this study was to combine baseline...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancers (Basel)
Autori principali: Dimitrakopoulos, Foteinos-Ioannis, Nikolakopoulos, Achilleas, Kottorou, Anastasia, Kalofonou, Fotini, Liolis, Elias, Frantzi, Theodora, Pyrousis, Ioannis, Koutras, Angelos, Makatsoris, Thomas, Kalofonos, Haralabos
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7280986/
https://ncbi.nlm.nih.gov/pubmed/32429368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12051257
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi